The Keratin 6B belongs to the keratin gene family, with type II of cytokeratin consisting of basic or neutral proteins arranged in pairs of heterotypic keratin chains. The product has been identified as an effective research product, with the makers expressly stating that it is made exclusively for research purpose and not intended for human or diagnostic use.
The Keratin antibody is synthetic peptide immunogen with human reactivity. It can be applied in IF, IHC-p, WB and it is advised that the optimal working dilutions are to be determined through experiments by the investigator. The researcher at Abbkine have however suggested starting dilutions of WB: 1:1000.
The monoclonal antibody, CK 6A antibody, is hosted in the mouse, with a Mouse IgG1 isotype and went through state-of-the-art purification process. The product was affinity-purified from mouse ascites by affinity-chromatography with the use of specific immunogen.
The product is available in a liquid solution with a 1 mg/ml concentration and can be stored for up to twelve months from the date of shipment if stored at a stable temperature of -20 °C.
About Abbkine Scientific
Abbkine Scientific has grown to become a household name in the field of life science research, providing top-notch research tools and products to investigators and scientific researchers across the globe.
The company was established in 2012 in United States but moved its headquarters to China in a bid to meet growing demand from the region.
Cancer is one of the leading causes of death, and there is great interest in understanding the underlying molecular mechanisms involved in the pathogenesis and progression of individual tumors. Mathias Uhlen at KTH–Royal Institute of Technology in Stockholm, Sweden and his colleagues used systems-level approaches to analyze the genome-wide transcriptome of the protein-coding genes of 17 major cancer types with respect to clinical outcome. A general pattern emerged: Shorter patient survival was associated with up-regulation of genes involved in cell growth and with down-regulation of genes involved in cellular differentiation. Using genome-scale metabolic models, they show that cancer patients have widespread metabolic heterogeneity, highlighting the need for precise and personalized medicine for cancer treatment. All data are presented in an interactive open-access database (www.proteinatlas.org/pathology) to allow genome-wide exploration of the impact of individual proteins on clinical outcomes.
Haplotype-resolved genome sequencing promises to unlock a wealth of information in population and medical genetics. However, for the vast majority of genomes sequenced to date, haplotypes have not been determined because of cumbersome haplotyping workflows that require fractions of the genome to be sequenced in a large number of compartments. Here Fan Zhang at Advanced Research Department, Illumina in San Diego, California, USA and his colleagues demonstrate barcode partitioning of long DNA molecules in a single compartment using “on-bead” barcoded tagmentation. The key to the method that they call “contiguity preserving transposition” sequencing on beads (CPTv2-seq) is transposon-mediated transfer of homogenous populations of barcodes from beads to individual long DNA molecules that get fragmented at the same time (tagmentation). These are then processed to sequencing libraries wherein all sequencing reads originating from each long DNA molecule share a common barcode. Single-tube, bulk processing of long DNA molecules with ~150,000 different barcoded bead types provides a barcode-linked read structure that reveals long-range molecular contiguity. This technology provides a simple, rapid, plate-scalable and automatable route to accurate, haplotype-resolved sequencing, and phasing of structural variants of the genome.